BPN711: Point-of-Care System for Quantitative Measurements of Blood Analytes Using Graphene-Based Sensors

Project ID

BPN711

Website

Start Date

Fri 2013-Feb-01 10:13:06

Last Updated

Tue 2017-Aug-15 10:18:52

Abstract

Serum glucose, cholesterol, triglyceride and HbA1C monitoring are all valuable tools in the health
management of the aging population, especially given the increase in diabetes and cardiovascular
diseases. Even for glucose monitoring, the challenges obtaining sufficiently accurate and reliable
measurements are so significant that the FDA is contemplating more stringent standards. Guido
Freckmann, et al., J. Diabetes Sci. Tech. 6, 1060-1075, 2012, have compared 43 blood glucose self-
monitoring systems. Out of this, 34 systems were completely assessed and 27 (79.4%) systems fulfilled
the minimal accuracy requirements and only 18 (52.9%) of 34 systems fulfilled the requirements of the
proposed tighter criteria in the current standards draft. None of them meet the even more stringent
requirement of ISO 2012 and FDA. Because inaccurate systems bear the risk of false therapeutic decisions
and rising health care costs, there is an urgent need for significantly enhanced BG monitoring systems for
PC applications. POC tests for other biomedically important analytes are generally even less accurate. The
overall goal of the proposed research is to develop new sensor platforms that will provide increased
sensitivity and accuracy in point-of-care situations. This is a joint project with Harvard Medical School and
Vanderbilt University.